The specific features of metabolism of DHEA and the current possibilities of its use for the correction of reproductive dysfunction
Objective. To present the characteristics of dehydroepiandrosterone (DHEA) metabolism and to consider species differences in the synthesis of DHEA.Goncharov N.P., Dedov I.I., Katsia G.V., Gavisova A.A., Sukhikh G.T.
Material and methods. The review includes the data of foreign and Russian articles published in the past years, which had been found in Pubmed on this topic.
Results. The paper proves the decisive role of DHEA as a source of the biologically active sex steroids testosterone and estrogens in peripheral tissues. It considers the bioavailability and possible mechanisms of action of DHEA. Experimental and clinical studies have revealed that the bioavailability of transdermal DHEA is higher than that of oral DHEA.
Conclusion. Most recent studies in men and women demonstrate the pronounced relationship of the body’s bioavailability of DHEA as an aqueous gel of water-insoluble steroids. The paper presents the authors’ technology for the transdermal administration of DHEA as an aqueous gel of water-insoluble C18, C19, and C21 steroids, by using deacetylated chitin (chitosan) as a carrier, which can substantially reduce the dose of the hormone administered.
Keywords
dehydroepiandrosterone (DHEA)
DHEA-S
chitin
chitosan
species characteristics
aging
biosynthesis
bioavailability
transdermal administration
Supplementary Materials
- Fig. 1. The average indices of the content of the main steroid hormones in peripheral blood in young men (according to the Laboratory of Biochemical Endocrinology and Hormonal Analysis of the State Institution of the Russian Academy of Medical Sciences)
- Fig. 2. Individual age dynamics of DHEA in men in the range of 23 – 112 years
References
1. Leinonen P., Ruokonen A., Kontturi M., Vihko R. Effects of estrogen treatment on human testicular unconjugated steroid and steroid sulfate production in vivo. J. Clin. Endocrinol. Metab. 1981; 53(3): 569-73.
2. McKenna T.J., DiPietro D.L., Brown R.D., Strott C.A., Liddle G.W. Plasma 17-OH-pregnenolone in normal subjects. J. Clin. Endocrinol. Metab. 1974; 39(5): 833-41.
3. Baulieu E.E., Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J. Endocrinol. 1996; 150(Suppl.): S221-39.
4. Goncharov N.P., Katsiya G.V., Dzhokua A.A., Barkaya V.S., Kulava Z.V., Mikvabiya Z.Y. Effect of neurosteroid dehydroepiandrosterone on the higher nervous activity of old non_human primates. Hum. Physiol. 2014; 40(2): 149-55.
5. Labrie F., Dupont A., Belanger A., Cusan L., Lacourciere Y., Monfette G. et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin. Invest. Med. 1982;5(4): 267-75.
6. Khalil M.W., Strutt B., Vachon D., Killinger D.W. Effect of dexamethasone and cytochrome P450 inhibitors on the formation of 7alpha- hydroxydehydroepiandrosterone by human adipose stromal cells. J. Steroid Biochem. Mol. Biol. 1994; 48(5-6): 545-52.
7. Luu-The V., Dufort I., Paquet N., Reimnitz G., Labrie F. Structural characterization and expression of the human dehydroepiandrosterone sulfotransferase gene. DNA Cell Biol. 1995; 14(6): 511-8.
8. Rhéaume E., Simard J., Morel Y., Mebarki F., Zachmann M., Forest M.G. et al. Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene. Nat. Genet. 1992; 1(4): 239-45.
9. Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bachvarov D. et al. Structure of human type II 5alpha-reductase gene. Endocrinology. 1992; 131(3): 1571-3.
10. Labrie F., Simard J., Luu-The V., Pelletier G., Bélanger A., Lachance Y. et al. Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/ 5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. J. Steroid Biochem. Mol. Biol. 1992; 41(3-8): 421-35.
11. Luu-The V., Zhang Y., Poirier D., Labrie F. Characteristics of human types 1, 2 and 3 17beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J. Steroid Biochem. Mol. Biol. 1995; 55(5-6): 581-7.
12. Labrie Y., Durocher F., Lachance Y., Turgeon C., Simard J., Labrie C., Labrie F. The human type II 17beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. DNA Cell Biol. 1995; 14(10): 849-61.
13. Labrie F., Simard J., Luu-The V. The 3-beta-hydroxysteroid dehydrogenase / isomerase gene family: lessions from type II 3beta-HSD congenital deficiency. In: Hansson V., Levy F. O., Tasken K., eds. Signal transduction in testicular cells. Ernst Schering Research Foundation Workshop. Berlin, Heidelberg, New York: Springer-Verlag; 1996: 185-218.
14. Stahl F., Schnorr D., Pilz C., Dörner G. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer ,heart diseases and under surgery stress. Exp. Clin. Endocrinol. 1992; 99(2): 68-70.
15. Labrie C., Martel C., Dufour J.M., Lévesque C., Mérand Y., Labrie F. Novel compounds inhibit estrogen formation and action. Cancer Res. 1992; 52(3):610-5.
16. Luo S., Sourla A., Labrie C., Gauthier S., Merand Y., Belanger A., Labrie F. Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology. 1998; 139(5): 2645-56.
17. Luu-The V., Labrie C., Simard J., Lachance Y., Zhao H.F., Couët J. et al. Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes. Mol. Endocrinol. 1990; 4(2): 268-75.
18. Labrie F., Bélanger A., Simard J., Van Luu-The, Labrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann. N. Y. Acad. Sci. 1995; 774: 16-28.
19. Studd J.W., Chakravarti S., Collins W.P. Plasma hormone profiles after the menopause and bilateral oophorectomy. Postgrad. Med. J. 1978; 54(Suppl. 2): 25-30.
20. Longcope C., Hui S.L., Johnston C.C. Jr. Free estradiol, free testosterone, and sex hormone-binding globulin in perimenopausal women. J. Clin. Endocrinol. Metab. 1987; 64(3): 513-8.
21. Steinberg K.K., Freni-Titulaer L.W., DePuey E.G., Miller D.T., Sgoutas D.S., Coralli C.H. et al. Sex steroids and bone density in premenopausal and perimenopausal women. J. Clin. Endocrinol. Metab. 1989; 69(3): 533-9.
22. Labrie C., Flamand M., Bélanger A., Labrie F. High bioavailability of dehydroepiandrosterone administered percutaneously in the rat. J. Endocrinol. 1996; 150(Suppl.): S107-18.
23. Wolkowitz O.M., Reus V.I., Roberts E., Manfredi F., Chan T., Raum W.J. et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol. Psychiatry. 1997; 41(3): 311-8.
24. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009; 16(5): 907-22.
25. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol. Endocrinol. 2010; 26(7): 524-32.
26. Labrie F., Archer D.F., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Intravaginal dehydroepiandrosterone ( prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011; 14(2): 282-8.
27. Labrie F., Archer D.F., Koltun W., Vachon A., Young D., Frenette L. et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016; 23(3):243-56.
28. Bouchard C., Labrie F., Derogatis L., Girard G., Ayotte N., Gallagher J. et al. Effect of intravaginal dehydroepi-androsterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm. Mol. Biol. Clin. Investig. 2016; 25(3): 181-90.
29. Schmid B.C., Rezniczek G.A., Rolf N., Saade G., Gebauer G., Maul H. Uterine packing with chitosan-covered gauze for control of postpartum hemorrhage. Am. J. Obstet. Gynecol. 2013; 209(3): 225. e1-5.
30. Labrie F., Belanger A., Simard J., Luu-The V., Labrie C. DHEA, The precursor of androgens and estrogens in peripheral tissues in the human: intracrinology. In: Kalimi M., Regelson W., eds. Dehydroepiandrosterone (DHEA). Berlin, New York: Walter de Gruyter; 2000: 299-342.
31. Labrie F., Archer D., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause. 2009; 16(5): 897-906.
32. Trivedi D.P., Khaw K.T. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J. Clin. Endocrinol. Metab. 2001; 80(9):4171-7.
33. Casson P.R., Lindsay M.S., Pisarska M.D., Carson S.A., Buster J.E. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum. Reprod. 2000; 15(10):2129-32.
34. Fouany M.R., Sharara F.I. Is there a role for DHEA supplementation in women with diminished ovarian reserve? J. Assist. Reprod. Genet. 2013; 30:1239-44.
35. Zhang J., Qiu X., Gui Y., Xu Y., Li D., Wang L. Dehydroepiandrosterone improves the ovarian reserve of women with diminished ovarion reserve and is a potential regulator of the immune response in the ovaries. Biosci. Trends. 2015; 9(6): 350-9.
36. Kotb M.M., Hassan A.M., AwadAllah A.M. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? Eur. J. Obstet. Gynecol. Reprod. Biol. 2016; 200: 11-5.
37. Qin J.C., Fan L., Qin A.P. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle. J. Gynecol. Obstet. Hum. Reprod. 2017; 46(1): 1-7.
Received 03.02.2017
Accepted 17.02.2017
About the Authors
Goncharov Nikolai Petrovich, MD, Professor, Head of the Laboratory of biochemical endocrinology and hormonal analysis, Endocrinology Research Center,Ministry of Health of Russia. 115478, Russia, Moscow, Moskvorechye str. 1. Tel.: +74993249529. E-mail: goncharovn@endocrincentr.ru
Dedov Ivan I., Ph.D., professor, academician of the Russian Academy of Sciences, Vice-President of RAS, Director of the Endocrinology Research Center,
Ministry of Health of Russia. 117036, Russia, Moscow, Dmitry Ulyanov str. 11. Tel.: +74995000090
Katsia Gulinara Viktorovna, MD, main researcher department of biochemical endocrinology and hormonal analysis, Endocrinology Research Center,
Ministry of Health of Russia. 115478, Russia, Moscow, Moskvorechye str. 1. Tel.: +74993249529.
Gavisova Alla Anatolievna, Candidate of Medical Science, Senior Researcher Department of Conservation and Restoration of the Reproductive Function,
Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. E-mail: gavialla@yandex.ru
Sukhikh Gennady Tihonovich, MD, professor, academician of the Russian Academy of Sciences, Director of the Research Center of Obstetrics,
Gynecology and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381800
For citations: Goncharov N.P., Dedov I.I., Katsia G.V., Gavisova A.A.,
Sukhikh G.T. The specific features of metabolism of dehydroepiandrosterone and the current possibilities of its use for the correction of reproductive dysfunction.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (7): 18-26. (in Russian)
http://dx.doi.org/10.18565/aig.2017.7.18-26
Similar Articles
